Status:
RECRUITING
Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis
Lead Sponsor:
Wake Forest University Health Sciences
Collaborating Sponsors:
Desert Harvest
Conditions:
Interstitial Cystitis
Chronic Interstitial Cystitis
Eligibility:
All Genders
18-80 years
Phase:
EARLY_PHASE1
Brief Summary
The purpose of this study is to assess the safety and efficacy of super-concentrated, freeze-dried aloe vera capsules for treatment of interstitial cystitis.
Detailed Description
After being informed about the study and potential risks, all participants who have provided written informed consent will be screened to determine eligibility for study entry. Participants who meet t...
Eligibility Criteria
Inclusion
- Females or males, aged 18 years or older
- Females of childbearing potential must agree to use acceptable methods of birth control. Acceptable methods are oral and injectable preparations, double barrier, vasectomized partner, or abstinence.
- Participant must sign and date the informed consent.
- Participant must report a urinary frequency of at least 11 times per 24-hour day, on average over the previous four weeks.
- Participant must report a pain/discomfort score of 4 or greater on a 0-9 Likert scale.
- These reported urinary symptoms of frequency and pain/discomfort must have been present for at least the previous 24 weeks prior to the first baseline screening visit.
- Participants must report in the baseline voiding diary at least one voided volume greater than or equal to 75cc in a 24-hour period.
Exclusion
- Known allergy or intolerance to aloe vera in any form as reported by the participant or derived from medical records.
- History of Bladder tumors (malignant or benign).
- Current active bladder or urethral calculus.
- History of urethral cancer within the previous five years.
- Any disease which, in the opinion of the investigator, may be unstable or have bearing on the outcome of the study, including severe debilitating concurrent medical conditions such as coronary artery disease, azotemia, moderate to severe hepatic insufficiency, etc.
- Previous treatment with Cytoxan (cyclophosphamide).
- History of cyclophosphamide or chemical cystitis or tuberculosis or radiation cystitis.
- History of pelvic radiation treatment, bladder cancer or cancer in situ, or urethral cancer.
- History of any other neoplastic process currently requiring systemic, nonprophylactic treatment.
- History of urethral diverticulum.
- Inability to void spontaneously.
- Subjects with interstitial cystitis symptoms alleviated by current therapy regimen.
- Uncontrolled diabetes mellitus.
- Previous enrollment in an aloe vera study.
- Previous use of Desert Harvest super-concentrated, freeze-dried aloe vera capsules.
- Any imminent change in residence that could compromise compliance.
- Unlikely to be compliant due to unmanaged medical or psychological problem, including dementia, aphasia, or other deficits of cognition or speech/language function that will interfere with the participant's ability to complete the study.
- Substance abuse or dependency problem within the past two years for which patient received no treatment.
- Male-Specific
Key Trial Info
Start Date :
February 18 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04734106
Start Date
February 18 2025
End Date
July 1 2027
Last Update
August 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest Baptist Hospital
Winston-Salem, North Carolina, United States, 27157